Physician profile
Cesar Giancarlo Gentille Sanchez
NPI 1215311600
$28,878.55
in general payments reported to CMS, 2019-2025
22 companies · $16K in 2025
The $16K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $150 · 2021: $336 · 2023: $281 · 2024: $11K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $6,285 · Travel and Lodging: $2,115 · Food and Beverage: $1,229 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,875.00 |
| Consulting Fee | $6,284.53 |
| Travel and Lodging | $2,114.84 |
| Food and Beverage | $1,229.46 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $11,816.36 | 2025 | Brukinsa |
| Beigene USA, INC. | $7,590.13 | 2021-2024 | Brukinsa |
| Acrotech Biopharma INC. | $7,299.15 | 2024-2025 | Beleodaq |
| Kyowa Kirin, INC. | $409.43 | 2023-2025 | Poteligeo |
| Genzyme Corporation | $405.60 | 2019-2025 | |
| Amgen INC. | $311.27 | 2019-2021 | |
| Incyte Corporation | $165.12 | 2019-2025 | Niktimvo |
| Jazz Pharmaceuticals INC. | $116.95 | 2019 | |
| Kite Pharma, INC. | $116.35 | 2023 | Yescarta |
| Glaxosmithkline, LLC. | $113.90 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $112.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.47 | 2019-2020 | |
| Celgene Corporation | $95.33 | 2019-2020 | |
| Pfizer INC. | $65.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.26 | 2021 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Gilead Sciences, INC. | $19.99 | 2023 | |
| Rigel Pharmaceuticals, INC. | $16.05 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Gentille Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.